Rilotumumab extends PFS in gastric cancer.
Patients with gastric or esophagogastric cancer treated with combination chemotherapy and rilotumumab, an anti-HGF monoclonal antibody, had longer progression-free survival than patients treated with chemotherapy alone, according to results from a phase II clinical trial. The survival benefit was greatest in patients with MET-positive disease; a phase III trial testing the drug combination's effect on this patient population is now under way.